08/21/2026
Food allergy research is moving in an encouraging direction. 👏🏻👏🏻
New findings from the OUtMATCH trial suggest that Xolair (omalizumab) may help some people with multiple food allergies tolerate larger amounts of foods they’re allergic to and reduce the risk of severe reactions from accidental exposure.
It’s important to remember: Xolair is not a cure for food allergies, and it doesn’t mean allergens are suddenly safe to eat. But for some patients, it may offer an added layer of protection—and that’s pretty exciting progress.
If you or your child is living with food allergies, talk with a member of our team about what treatment and management options may be appropriate for you.
📌 We’re sharing the original post from Food Allergy Research & Education (FARE) below for more information.
New research from the OUtMATCH trial offers encouraging insights for people living with multiple food allergies. Researchers found that about 1 in 3 patients treated with omalizumab (Xolair) were able to tolerate full servings (4,044 mg or more) of three different foods they were allergic to by the end of treatment period. The study also found that participants treated with omalizumab experienced fewer cases of anaphylaxis. While omalizumab is not a cure for food allergy, these findings add to growing evidence that it may help increase protection against accidental exposures for some people living with multiple food allergies. FARE is committed to advancing food allergy research and keeping our community informed about the latest scientific developments. As always, treatment decisions should be made in partnership with an allergist to determine the best approach for each individual's needs.
Read FARE's OUtMATCH Summary here: https://www.foodallergy.org/resources/biologics